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1. Introduction 
The regulation of connective tissue metabolism 
involves cell-cell interactions leading to modulation 
in the enzymic breakdown of collagen and proteo- 
glycans as well as in the synthesis rate of these macro- 
molecules. In many chronic inflammatory lesions, 
such as rheumatoid synovial pannus, numerous cell 
types (lymphocytes, monocytes, fibroblasts, endo- 
thelial cells) are closely associated. A substance pro- 
duced by an immune cell may influence the main 
functions of fibroblasts: proliferation, secretion of 
degradative enzymes (collagenase, proteoglycan- 
degrading proteases), and synthesis of collagen and 
proteoglycans. Experimental granuloma, tissue and 
cell culture have provided tools to detect a growing 
number of such factors [1-9]. 
A mononuclear cell factor that stimulates col- 
lagenase and prostaglandin production by rheumatoid 
synovial cells in culture has been isolated [10]. This 
work reports the inhibition of collagen and non-col- 
lagenous protein synthesis by synovial cells, induced 
by a factor(s) of mononuclear cell medium (MCM). 
This factor(s), in addition, significantly raises the 
level of glycosaminoglycan (GAG) production. Such 
biologically active monocyte-derived substance(s) 
might be involved in the connective tissue metabolism 
of inflammatory lesions. 
2. Materials and methods 
2.1. Culture of  synovial cells 
Synovial cells were obtained by enzymatic dissocia- 
tion from osteoarthritic surgical specimens as in [10], 
and maintained in DMEM, supplemented with 10% 
foetal calf serum (FCS), 2 lnM glutamine, penicillin 
(100 units/ml), streptomycin (100 #g/ml) and Fungi- 
zone (2.5/lg/ml). Experiments were performed on 
cells at first passage. 
2.2. Mononuclear cell medium (MCM) 
Mononuclear cells from blood of healthy donors 
were separated by centrifugation i  a Ficoll Metrizoate 
solution and incubated in McCoy medium, with 
phytohaegglutinin (40/ag/ml) as in [11 ]. After 3 days, 
the culture medium was collected, centrifuged and 
the supernatant s ored at -25°C. 
2.3. Incubation o f  synopial cells with MCM 
Synovial cells were plated at 2.5 × l0 s cells/Petri 
dish (6 cm) and grown to confluency. The medium 
was changed 24 h before experiment and the super- 
natant was added to the flesh medium at final dilu- 
tion o f l :10or  1:15. 
2.4. Collagen assay 
Cells were first incubated with 1.5 ml medium 
containing/3-aminopropionitrile (50/~g/ml) and 
ascorbic acid (10/lg/ml), with or without MCM. 
After 24 h, the medium was again replaced with 
medium containing the same additions plus 2.5-5 
/ICi/ml L-[4-5-3H]proline (20-30 Ci/mmol, CEA). 
At the end of the incubation, media and cells were 
precipitated separately with 5% trichloroacetic acid. 
Then the pellets were submitted to purified bacterial 
collagenase treatment as in [ 12] and the radioactivity 
of collagen and noncollagen proteins was determined. 
2.5. Glycosaminoglycan ssay 
Confluent cultures were incubated in DMEM, 10% 
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FCS in presence of [ 1-3H] glucosamine (2.5/aCi/ml); 
spec. act. 11 Ci/mmol) for 78 h. Radioactive GAG 
present in the culture medium (extracellular pool), 
in the supernatant obtained after trypsinisation of 
the cells (pericellular pool) [13] and in the cell 
pellet (intracellular pool) were prepared as in [ 11 ]. 
The radioactivities of these fractions were assayed by 
liquid scintillation counting after dissolution in dis- 
tilled water. 
3. Results 
3.1. Kinetics of collagen production 
Exposure of synovial cells to a 1:10 dilution of 
MCM resulted in a dramatic decrease in the production 
of [3H] proline-labeled protein, which was susceptible 
to digestion by collagenase (fig. 1 a). This inhibitory 
effect could be detected after only 6 h incubation 
and, by 48 h, a 90% inhibition of collagen production 
in the medium was observed. Cell-associated collagen 
exibited a similar decrease which began later, between 
12-24 h exposure (fig. 1 b). The small difference 
between control and treated cells observed prior 12 h 
was not significant. When expressed as % of total 
collagen radioactivity, the cell content of exposed 
cultures displayed aprofile similar to controls (fig. 1 c). 
This demonstrates that there was no accumulation of 
collagen inside the cells and that the secretion of this 
protein was not affected. The decrease in collagen 
production cannot be accounted for by a decrease in 
cell number since experiments were done at cell con- 
fluency, with a fairly constant cell density as shown 
by enumerations made at the end of treatment. Also 
practically excluded was the inhibitory effect of 
prostaglandin PGE2 on the proliferation rate of 
synovial cells, occuring after exposure to MCM [ 10]. 
In addition, the viability of cells was not affected in 
our experiments, as judged by the trypan blue exclu- 
sion test. 
Fig.1. Effect of MCM on collagen synthesis by synovial cells 
in culture: (a) Collagen production in the culture medium; 
incubation with 2.5 ~Ci/ml [3H]proline; data represent mean 
of duplicate cultures; (b) collagen content of the cell layer; 
(c) collagen of the cell layer expressed as % of total collagen; 
control cultures ( - . - ) ;  MCM-treated cultures ( -o  ). 
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Table 1 
Effect of two different preparations of MCM (MCM~ and MCM 2) on synovial cell 
collagen and non-collagen protein production 
Collagen Non-collagen protein 
dpm X 10 -~ cells % dpm X 10 -6 cells % 
Control 87 290 100 116 043 100 
MCM~ 1:15 61 827 70.8 115 102 99.2 
MCM 1 1:10 59 741 68.4 111 214 95.8 
Control 87 290 100 116 043 100 
MCM~ 1:15 51 016 58.4 88 695 76.4 
MCM~ 1:10 41 220 47.2 76404 65.8 
Cultures were exposed to 1:10 and 1:15 dilutions of MCM and labeled with 5 ~Ci/ml 
[3H]proline during the last 48 h. Medium was assayed for collagen and non-collagen 
protein. Data represent mean of duplicate cultures 
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3.2. Non-collagen proteins 
The decrease in protein synthesis was not specific 
to collagen since production of non-collagenase- 
sensitive proteins was also reduced, though to a lower 
extent. The effect of MCM on non-collagen protein 
varied with the MCM preparation and the dilution 
used. As shown in table 1, some preparations which 
produced little effect on non-collagen protein produc- 
tion could still exert a significant decrease on collagen 
synthesis (~30%). Thus, collagen was more sensitive 
to MCM than non-collagen protein synthesis. 
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Fig.2. Effect of MCM on GAG synthesis by synovial cells in 
culture. (a) Intracellular pool;incubation with 2.5 ~Ci/ml 
[ 3 H ]glucosamine; data represent mean of duplicate cultures; 
(b) pericellular pool; (c) culture medium;control cultures 
( -e - ) ;  MCM-treated cultures ( -e - ) .  
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3.3. Glycosaminoglycans 
Synovial cells exposed to MCM synthesized 
increased GAG levels since the radioactivity of cellu- 
lar (fig.2a) and pericellular (fig.2b) pools from treated 
cultures were 2-2.5-times higher than in the controls. 
GAG production in the medium of the control cul- 
tures increased within 24 h and then remained rela- 
tively constant. In contrast, cells exposed to MCM 
secreted increasing amount of radioactive GAG up to 
78 h, at which time the level of newly synthesized 
GAG present in the medium was 4-times greater than 
the control (fig.2c). However, the relative distribution 
of labeled GAG in the different pools was not affected 
by MCM (fig.3). 
4. Discussion 
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Fig.3. GAG content of the different fractions expressed as% 
of total GAG: (a) intracellular pool; (b) pericellular pool; (c) 
culture medium; control cultures ( • ); MCM-treated cul- 
tures ( -o ) .  
This work shows that stimulated peripheral blood 
monocytes contain a factor(s) which affects ynovial 
cells in culture, depressing markedly collagen syn- 
thesis and other protein synthesis, though to a smaller 
extent, while enhancing GAG production. MCM has 
also been shown to decrease collagen eosynthesis 
in skin fibroblasts [ 14], without affecting non-collagen 
protein production. This difference might be related 
to the MCM preparation used as shown in table 1. The 
decrease in collagen content of MCM-treated cultures 
cannot be explained by extracellular enzymic degra- 
dation since collagenase secreted into the medium 
was inhibited by serum and has to be demonstrated 
by previous proteolytic activation [ 10,11 ]. 
MCM enhances hyaluronic acid secretion by syno- 
vial cells in culture [I 1]: this work extends that find- 
ing to the totality of the GAGproduced by these cells. 
A mononuclear cell factor capable of increasing 
collagenase and prostaglandin PGE2 release by syno- 
vial cells has been isolated [15]. We do not know 
whether the same molecule is also involved in the 
modulation of collagen and GAG synthesis observed 
in our work. Further investigations, in progress, are 
needed to clarify this point. 
PGE2 is known to be a relatively specific inhibitor 
of collagen synthesis by osteoblasts [16]. It can also 
increase hyaluronic acid production by synovial 
fibroblasts [ 17,18] and GAG biosynthesis n skin 
fibroblasts [19]. So, the effects observed in our exper- 
iments could be related to the secondary influence of 
a rise in PGE2 release by MCM-treated synovial cells 
[10]. They cannot be due to contaminating amounts 
of PGE2 already present in monocyte-conditioned 
medium since the production of PGE2 by monocytes 
is insignificant compared to that produced by the 
synovial cells exposed to MCM [20]. 
Although the inflamed synovial tissue is infiltrated 
with monocytes, the relevance of these findings to 
the pathogenesis of rheumatoid arthritis is not clear 
since they do not completely integrate the flbroblastic 
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response occurring during chronic inflammation. 
They only provide some explanation for a part of the 
events which modulate collagen and GAG produc- 
tion. For example, the present experiments could not 
explain the increased collagen content observed in 
rheumatoid synovial tissue as compared to normal 
tissue [21-23].  However, other cell-types present in 
inflammation can produce substances which stimulate 
collagen synthesis in fibroblasts, i.e., counteracting 
the action of MCM. Such factors have been reported 
in lymphocytes [5 ], macrophages [6] and platelets 
[8]. Furthermore, it has been shown that connective 
tissue activating factors can be detected in the pro- 
liferation phase of the inflammation process whereas 
inhibitory substances appear as the disease progresses 
[24,25]. These studies uggest, herefore, that there 
is normally an adequate balance between stimulation 
and inhibition, but which may be perturbed under 
certain conditions resulting in either deficient or 
excessive accumulation of connective tissue macro- 
molecules. The monocyte derived factor may be 
involved in this process as one of these factors. 
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